How to buy Frequency Therapeutics stock | 23.45

Frequency Therapeutics, Inc is a biotechnology business based in the US. Frequency Therapeutics shares (FREQ) are listed on the NASDAQ and all prices are listed in US Dollars. Frequency Therapeutics employs 43 staff and has a trailing 12-month revenue of around USD$44.7 million.

How to buy shares in Frequency Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Frequency Therapeutics. Find the stock by name or ticker symbol: FREQ. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Frequency Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$23.45, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Frequency Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Frequency Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Frequency Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Frequency Therapeutics's share price has had significant negative movement.

Its last market close was USD$23.45, which is 4.64% down on its pre-crash value of USD$24.59 and 50.88% up on the lowest point reached during the March crash when the shares fell as low as USD$15.5425.

If you had bought USD$1,000 worth of Frequency Therapeutics shares at the start of February 2020, those shares would have been worth USD$665.96 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$880.31.

Frequency Therapeutics share price

Use our graph to track the performance of FREQ stocks over time.

Frequency Therapeutics shares at a glance

• Key figures

Information last updated 2020-10-19.

Latest market close	USD$23.45
52-week range	USD$13.6 - USD$28.78
50-day moving average	USD$20.6806
200-day moving average	USD$19.9057
Wall St. target price	USD$35
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.6355

Buy Frequency Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Frequency Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Frequency Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Frequency Therapeutics price performance over time

Historical closes compared with the close of $23.45 from 2020-11-16

1 week (2020-11-23)	-13.98%
1 month (2020-10-30)	7.18%
3 months (2020-08-28)	19.34%
6 months (2020-05-29)	26.35%

1 year (2019-11-29)	40.42%
2 years (2018-11-26)	N/A
3 years (2017-11-26)	N/A
5 years (2015-11-26)	N/A

Frequency Therapeutics financials

Revenue TTM	USD$44.7 million
Gross profit TTM	USD$12.9 million
Return on assets TTM	-10.22%
Return on equity TTM	-17.75%
Profit margin	-38.02%
Book value	N/A
Market capitalisation	USD$743.2 million

TTM: trailing 12 months

Shorting Frequency Therapeutics shares

There are currently 4.2 million Frequency Therapeutics shares held short by investors – that's known as Frequency Therapeutics's "short interest". This figure is 2.2% up from 4.1 million last month.

There are a few different ways that this level of interest in shorting Frequency Therapeutics shares can be evaluated.

Frequency Therapeutics's "short interest ratio" (SIR)

Frequency Therapeutics's "short interest ratio" (SIR) is the quantity of Frequency Therapeutics shares currently shorted divided by the average quantity of Frequency Therapeutics shares traded daily (recently around 222119.11298838). Frequency Therapeutics's SIR currently stands at 18.94. In other words for every 100,000 Frequency Therapeutics shares traded daily on the market, roughly 18940 shares are currently held short.

However Frequency Therapeutics's short interest can also be evaluated against the total number of Frequency Therapeutics shares, or, against the total number of tradable Frequency Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Frequency Therapeutics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Frequency Therapeutics shares in existence, roughly 130 shares are currently held short) or 0.1377% of the tradable shares (for every 100,000 tradable Frequency Therapeutics shares, roughly 138 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Frequency Therapeutics.

Find out more about how you can short Frequency Therapeutics stock.

Frequency Therapeutics share dividends

We're not expecting Frequency Therapeutics to pay a dividend over the next 12 months.

Frequency Therapeutics overview

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Frequently asked questions

• What percentage of Frequency Therapeutics is owned by insiders or institutions?

  Currently 16.074% of Frequency Therapeutics shares are held by insiders and 44.417% by institutions.

• How many people work for Frequency Therapeutics?

  Latest data suggests 43 work at Frequency Therapeutics.

• When does the fiscal year end for Frequency Therapeutics?

  Frequency Therapeutics's fiscal year ends in December.

• Where is Frequency Therapeutics based?

  Frequency Therapeutics's address is: 19 Presidential Way, Woburn, MA, United States, 01801

• What is Frequency Therapeutics's CUSIP number?

  Frequency Therapeutics's Committee on Uniform Securities Identification Procedures number is: 35803L108